Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

Ligand Pharmaceuticals Target Price

Analysts' average 12-month price target for Ligand Pharmaceuticals is $340.

Get informed when a big investor buys or sells

+ Follow

Share Price

$285.6

Average Target Price

$338.50

18.5% upside

6 analysts in the last 4 months

High: $358 | Low: $326

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-14	Leerink Partners	$330	15.5% upside
2026-08-06	H.C. WainwrightJoseph Pantginis	$358	25.4% upside
2026-08-03	OppenheimerLeland Gershell	$326	14.1% upside
2026-07-20	Craig-HallumMatt Hewitt	$345	20.8% upside
2026-07-15	RBC Capital	$340	19% upside
2026-07-08	Stifel NicolausAnnabel Samimy	$332	16.2% upside
2026-04-30	H.C. WainwrightJoseph Pantginis	$289	1.2% upside
2026-04-28	RBC Capital	$252	11.8% downside
2026-04-27	Stifel Nicolaus	$255	10.7% downside
2026-04-14	H.C. WainwrightJoseph Pantginis	$243	14.9% downside
2026-02-24	H.C. WainwrightJoseph Pantginis	$239	16.3% downside
2025-12-10	Stifel Nicolaus	$230	19.5% downside
2025-12-10	OppenheimerTrevor Allred	$275	3.7% downside
2025-11-06	Stifel NicolausAnnabel Samimy	$220	23% downside
2025-11-06	H.C. Wainwright	$231	19.1% downside
2025-11-03	OppenheimerLeland Gershell	$250	12.5% downside
2025-09-03	OppenheimerLeland Gershell	$190	33.5% downside
2025-08-28	H.C. Wainwright	$206	27.9% downside
2025-02-28	UBS	$155	45.7% downside
2024-10-21	H.C. WainwrightJoseph Pantginis	$157	45% downside
2024-10-02	OppenheimerLeland Gershell	$135	52.7% downside
2024-07-30	RBC CapitalDouglas Miehm	$130	54.5% downside
2024-07-09	Craig-HallumMatt Hewitt	$140	51% downside
2024-06-28	H.C. WainwrightJoseph Pantginis	$144	49.6% downside
2022-12-23	Roth Capital	$90	68.5% downside

Ligand Pharmaceuticals (LGND) FAQ

Ligand Pharmaceuticals (LGND) currently reports a target price of $340. Use the charts on this page to explore Ligand Pharmaceuticals's target price history and peer comparisons.

Analysts' average 12-month price target for Ligand Pharmaceuticals is $340, about 18.5% upside from the current share price of $285.6. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $340, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Ligand Pharmaceuticals, and consider following LGND for alerts when major investors trade the stock.

Ligand Pharmaceuticals is classified in the Healthcare sector. On target price, it currently shows $340. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LGND with unrelated industries.